FlexTrade Launches FlexNOW Execution Management System (EMS)
FlexTrade (@FlexTrade) today announced the official release of FlexNOW, an out-of-the-box, broker neutral EMS to address the needs of hedge funds and mini-primes who require a streamlined, multi-asset trading system at the click of a button.
Multi-Asset, MiFID II Compliant Trading -- Designed to handle trading for equities, futures and options, FlexNOW is MiFID II compliant; provides connectivity to leading market data providers; easily integrates with any order management system (OMS) via FIX and API; and comes with its own built-in transaction cost analysis functionality.
Easy Installation -- According to Rhyd Lewis, FlexNOW Product Manager at FlexTrade UK, FlexNOW’s zero-touch onboarding and installation process gets clients up and running in a matter of minutes. “By combining the one-click installation process with secure, online connectivity, we have greatly reduced the on-boarding lead time for customers,” said Lewis.
Streamlined Trading Workflows -- “We developed FlexNOW based on FlexTrade's industry experience and the feedback of our clients and prospects,” continued Lewis. “It’s this user research that helps us provide fresh updates to the platform to keep the trading workflows as effective as possible.”
Currently available in Europe, the Middle East and Africa, FlexNOW already has more than 200 live users with firms such as Albar Capital, PSG Capital and Wesleyan Assurance Society recently joining as new clients. FlexNOW’s availability across other regions of the globe will be announced in the coming months.
"We chose FlexNOW based on FlexTrade's proven track record in the trading technology space, the easy installation process, and connectivity to our brokers and RMS. Overall, we find FlexNOW to be an easy-to-use EMS that allows us to focus on trading and best execution," said Chris Beton, CTO/CRO at Everett Capital Advisors.
"FlexTrade is doing a great job for us," said Michael Perry, COO of Albar Capital. "Their collaborative approach and fast response time means that we regularly see the benefits of our feedback incorporated in a same-day platform update."
FlexTrade will be showcasing a live demo of FlexNOW at booth 15 during TradeTech Europe at the Palais des Congrès in Paris, April 25-26.
To find out more about FlexNOW or to request a demo, please contact us at email@example.com
About FlexTrade Systems, Inc.
Founded in 1996, FlexTrade Systems, Inc. is the industry pioneer in broker-neutral algorithmic trading platforms for equities, foreign exchange and listed derivatives. With offices in North America, Europe and Asia, FlexTrade has a worldwide client base spanning more than 200 buy-side and sell-side firms, including many of the largest hedge funds, asset managers, commodity trading advisors, investment banks and institutional brokers. For more information, visit FlexTrade Systems at www.flextrade.com.
FlexTrade Systems, Inc.
James Tolve, 516-304-3601
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Cytox Expands Collaboration with AIBL to Identify Those Most at Risk to Rapidly Progress to Alzheimer’s24.9.2018 05:00 | Pressemelding
Cytox, a precision medicine company which today is commercializing polygenic risk scoring (PRS) approaches for assessing genetic risk for developing Alzheimer’s disease (AD) and other neurological diseases, has announced it has expanded its research collaboration with the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) to test new algorithms for identifying the pre-symptomatic and mild cognitively impaired people most at risk to progress to AD. Under the expanded agreement Cytox will assess genetic risk for accelerated development of AD using its current, commercially available, research use only approaches developed to run on the Thermo Fisher Scientific Applied Biosystems™ GeneTitan™ Multi-Channel (MC) instrument platform. AIBL will provide biobank samples together with associated longitudinal data from study research participants clinically diagnosed as cognitively normal, with mild cognitive impairment or with AD. Each subject has confirmed amyloid status
American Airlines Announces Nonstop Philadelphia (PHL) to Orlando Melbourne (MLB)21.9.2018 22:13 | Pressemelding
Glorious beaches by day and theme park fireworks by night just got more convenient for Philadelphia travelers. American Airlines announced today that it will begin nonstop flights to Orlando Melbourne International Airport (MLB) starting February 16, 2019. The Central Florida airport is conveniently located in the heart of the tourism region and is the closest airport to NASA rocket launches, Port Canaveral’s cruises and what critics call “some of the most beautiful beaches Florida has to offer.” The flights will depart Saturdays from Philadelphia at 8:05 a.m., arriving in Florida at 10:48 a.m. The Embraer 175 jet arrival time syncs perfectly with cruise ship noon early boarding. Melbourne Airport Express offers nonstop shuttle service to the port, and all major rental car companies are onsite. The return flight to PHL departs at 11:24 a.m. and arrives in PHL at 1:55 p.m., with enough time to connect to some of American’s largest international destinations, including recently announced
Amy Palladino Joins BCW as Executive Vice President, Managing Director, Corporate Practice21.9.2018 17:43 | Pressemelding
BCW (Burson Cohn & Wolfe), a leading global communications agency, today announced that Amy Palladino has joined the agency as Executive Vice President, Managing Director in the agency’s U.S. Corporate Practice. Based in New York, Palladino will focus on senior client counsel and executive positioning for the agency’s largest corporate clients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005507/en/ Amy Palladino Joins BCW (Burson Cohn & Wolfe) “Amy is a talented and highly experienced communications executive with a track record of solving clients’ complex challenges and building business through smart, integrated communications approaches,” said Chris Foster, President, North America, BCW. “Her creativity and judgement will be enormously valuable to our current and prospective clients.” Palladino has more than 20 years of experience advising global clients across numerous industries, including technology, healthcar
Heidelberg Engineering Announces the CE-Marking of ANTERION21.9.2018 16:41 | Pressemelding
Heidelberg Engineering, the leader in diagnostic imaging known for the internationally-acclaimed SPECTRALIS ® retina and glaucoma platform, announces the CE-marking of ANTERION ® – an innovative platform designed to transform anterior segment diagnostics and workflow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005442/en/ The new Heidelberg Engineering ANTERION® provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. (Graphic: Business Wire) The new ANTERION provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. It is a single, workflow-efficient solution that brings together corneal topography and tomography, anterior segment metrics, axial length measurement and IOL calculation to transform the day-to-day routine of busy practices and clinics. Heidelberg Engineering has leveraged its core OCT technolo
Florian Winterstein Becomes New CEO of Jedox21.9.2018 15:46 | Pressemelding
The supervisory board of Jedox AG, a leading vendor of business intelligence and enterprise planning software, has appointed Florian Winterstein as Chief Executive Officer (CEO) effective October 2, 2018. This nomination will support Jedox’s international growth and a new development phase initiated by its latest fund raising in April 2018 with Iris Capital, eCAPITAL entrepreneurial Partners AG and Wecken & Cie. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005416/en/ Florian Winterstein (Photo: Business Wire) With 25 years of experience in strategy consulting and leadership in software and service organizations, Winterstein brings to the company a valuable combination of expertise in cloud solutions, business development, and value creation for customers and partners. As former Chief Strategy Officer of BravoSolution, he positioned the software-as-a-service company as trendsetting digitalization partner, extending it
Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib21.9.2018 13:30 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the full approval of ALUNBRIG® (brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib. ALUNBRIG is a tyrosine kinase inhibitor (TKI) designed to target and inhibit the ALK mutation in NSCLC. Approximately three to five percent of NSCLC patients globally have the ALK mutation. If the CHMP opinion is affirmed, and the European Commission approves ALUNBRIG, it will become the only ALK inhibitor available in the European Union as a one tablet per day dose that can be taken with or without food. The randomized, global Phase 2 ALTA trial was designed to investigate the efficacy and safety of ALUNBRIG in patients with locally advanced or metastatic ALK+